Patents by Inventor William Douglas Figg

William Douglas Figg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE
    Publication number: 20230135524
    Abstract: Disclosed is a compound of formula (I) in which R1, R2, R3, X1, X2, X2?, X3, X4, ring A, m, n, and o are as described herein. The compound of formula (I) is useful for treating a disorder associated with androgen receptor malfunction, such as a hyperproliferative disorder, in a subject in need thereof.
    Type: Application
    Filed: January 20, 2021
    Publication date: May 4, 2023
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, Georgia Tech Research Corporation
    Inventors: Berkley E. Gryder, Adegboyega K. Oyelere, Subhasish Tapadar, Jonathan D. Strope, William Douglas Figg, Sr.
  • Thalidomide analogs and methods of use
    Patent number: 11440880
    Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: September 13, 2022
    Assignees: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of Aberdeen
    Inventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
  • THALIDOMIDE ANALOGS AND METHODS OF USE
    Publication number: 20210047267
    Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.
    Type: Application
    Filed: October 29, 2020
    Publication date: February 18, 2021
    Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of Aberdeen
    Inventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
  • Thalidomide analogs and methods of use
    Patent number: 10836721
    Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: November 17, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University Court of the University of Aberdeen
    Inventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
  • THALIDOMIDE ANALOGS AND METHODS OF USE
    Publication number: 20200325102
    Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 15, 2020
    Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of Aberdeen
    Inventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
  • Thalidomide analogs and methods of use
    Patent number: 10730835
    Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: August 4, 2020
    Assignees: The United States of America, as represented by the Secretary, Health and Human Services, University Court of the University of Aberdeen
    Inventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
  • THALIDOMIDE ANALOGS AND METHODS OF USE
    Publication number: 20180273472
    Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 27, 2018
    Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of Aberdeen
    Inventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
  • PROGNOSTIC MARKERS AND METHODS FOR PROSTATE CANCER
    Publication number: 20130039908
    Abstract: The present invention relates to methods and compositions for the diagnosis, prognosis and treatment of neoplastic disorders. Some embodiments include methods, compositions, and kits for the prognosis and treatment of prostate cancer.
    Type: Application
    Filed: August 12, 2010
    Publication date: February 14, 2013
    Applicant: University of South Alabama
    Inventors: Eddie Reed, Rui Gao, William Douglas Figg